Overview

SORAVE - Sorafenib and Everolimus in Solid Tumors

Status:
Completed

Trial end date:
2015-02-01

Target enrollment:

Participant gender:

Summary

Dose finding part: A phase I clinical trial to evaluate the safety of combined sorafenib and everolimus treatment in patients with relapsed solid tumors (finished). Extension part:Treatment of non-small cell lung cancer (NSCLC) with KRAS mutation after ≥ 1st relapse (recruiting)

Phase:

Phase 1

Details

Lead Sponsor:

University of Cologne

Treatments:

Everolimus
Niacinamide
Sirolimus
Sorafenib